Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002285 · ClinicalTrials.gov registry record · NA
A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002285: Completed NA study, sponsored by Glaxo Wellcome.
NCT00002285 is a NA study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002285, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To determine the safety and efficacy of zidovudine (AZT) treatment combined with syngeneic or HLA identical allogeneic lymphocyte transfer in the presence of interleukin 2 (IL-2) as a treatment for AIDS. Patients with documented HIV viremia will be evaluated. Effects on virus replication, immune function, and clinical condition will be monitored with periodic virus cultures, estimates of lymphocyte type and numbers, cell surface markers, in vitro lymphocyte responses and frequent clinical evaluations.
Interventions
- DRUG Zidovudine
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002285 record still lists
NCT00002285 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Zidovudine is the first listed.
NCT00002285 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002285 about?
NCT00002285 is a clinical study titled "A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS". To determine the safety and efficacy of zidovudine (AZT) treatment combined with syngeneic or HLA identical allogeneic lymphocyte transfer in the presence of interleukin 2 (IL-2) as a treatment for AIDS. Patients with documented HIV viremia will be evaluated. Effects on virus replication, immune fun...
What is the current status of trial NCT00002285?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002285?
The interventions under investigation include: Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00002285?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.